Yin, Y., Xiao, J., Su, L., Lin, R. (2026). An early on-treatment "coordinated inflammatory niche" plasma signature as a predictor of response in the SYLT026 trial: Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite-stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3600